We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
Read MoreHide Full Article
Key Takeaways
QURE has rallied sharply as investors price in progress for AMT-130 before key regulatory proof points.
uniQure trades at a premium price-to-book multiple, leaving less room for execution setbacks or delays.
QURE has cash into the second half of 2029, but profitability and regulatory execution remain key watchpoints.
uniQure N.V. (QURE - Free Report) has surged as investors reassessed AMT-130, its lead gene therapy candidate for Huntington's disease.
The question is whether the move already reflects too much optimism. Valuation, earnings quality, estimate trends and ratings point to selective caution.
QURE Has Rallied Ahead of Key Proof Points
QURE has climbed 124.4% over the past 12 weeks and 159.0% over the past 52 weeks. Sentiment has reset quickly around AMT-130.
That rally raises the execution bar. AMT-130 remains the main value driver, and investors are pricing in progress before regulatory and commercial proof points are complete.
uniQure’s Valuation Already Looks Demanding
The stock trades at 16.48X price-to-book value. That is above 2.59X for its industry and 3.69X for the S&P 500, leaving valuation tied heavily to AMT-130.
A premium can be reasonable for a program targeting Huntington's disease, where no disease-modifying treatment is currently approved. Still, this multiple gives investors less room for delay, tougher feedback or slower launch preparation.
QURE’s Earnings Picture Is Still Uneven
First-quarter 2026 results were mixed. uniQure reported a loss of 85 cents per share, narrower than the Zacks Consensus Estimate of a loss of 88 cents but wider than the year-ago loss of 82 cents.
Revenues rose to $3.6 million from $1.6 million a year earlier, helped by higher license revenues and Hemgenix royalties under the CSL Behring collaboration. The top line missed the Zacks Consensus Estimate of $7 million.
Selling, general and administrative expenses rose 84% to $20.1 million on commercial hiring and higher professional, intellectual property and information technology costs tied to AMT-130 launch preparation. That spending reinforces the near-term loss profile.
PTC Therapeutics (PTCT - Free Report) and Wave Life Sciences (WVE - Free Report) give investors other Huntington's disease-related stocks to monitor. Their presence makes QURE's post-rally valuation discipline more important.
uniQure Has Some Estimate Support
The last earnings surprise was positive at 3.4%, and the current fiscal-year earnings estimate improved 2.3% over the past four weeks. QURE also had an Earnings Surprise Prediction of 12.0% ahead of the next expected report date.
Those data points help sentiment. They do not settle the larger questions around regulatory alignment, commercialization timing or the path to profitability.
QURE’s Balance Sheet Helps Offset the Risk
uniQure ended the first quarter with $586.6 million in cash, cash equivalents and investments. Management expects those resources to fund operations into the second half of 2029.
That runway gives the company time to pursue AMT-130 regulatory milestones and continue selected pipeline investment. It also reduces the immediate financing pressure common among clinical-stage biotechnology stocks.
The operating model has become cleaner as well. The remaining HEMGENIX supply obligations and minimum purchase commitments are expected to end after delivery of specified batches in mid-2026, without affecting future royalties or milestones.
Roche Holding AG (RHHBY - Free Report) , a broader healthcare peer, gives investors a more diversified comparison point. QURE remains the more concentrated AMT-130-driven story.
Why QURE’s Ratings Stay Mixed
The bottom line is that QURE's rally has improved the market's view of the story, but it has not removed the need for caution. The stock looks most relevant for investors comfortable with catalyst-driven biotechnology risk.
The Style Scores show the split. QURE has a Momentum Score of B, suggesting constructive price action, but its Value Score of F, Growth Score of F and VGM Score of F show that it does not screen broadly well on traditional valuation, growth and blended factors. That mix fits a selective, catalyst-focused view rather than a broadly bullish call.
View the Zacks #1 Rank List
Image: Bigstock
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
Key Takeaways
uniQure N.V. (QURE - Free Report) has surged as investors reassessed AMT-130, its lead gene therapy candidate for Huntington's disease.
The question is whether the move already reflects too much optimism. Valuation, earnings quality, estimate trends and ratings point to selective caution.
QURE Has Rallied Ahead of Key Proof Points
QURE has climbed 124.4% over the past 12 weeks and 159.0% over the past 52 weeks. Sentiment has reset quickly around AMT-130.
That rally raises the execution bar. AMT-130 remains the main value driver, and investors are pricing in progress before regulatory and commercial proof points are complete.
uniQure’s Valuation Already Looks Demanding
The stock trades at 16.48X price-to-book value. That is above 2.59X for its industry and 3.69X for the S&P 500, leaving valuation tied heavily to AMT-130.
A premium can be reasonable for a program targeting Huntington's disease, where no disease-modifying treatment is currently approved. Still, this multiple gives investors less room for delay, tougher feedback or slower launch preparation.
QURE’s Earnings Picture Is Still Uneven
First-quarter 2026 results were mixed. uniQure reported a loss of 85 cents per share, narrower than the Zacks Consensus Estimate of a loss of 88 cents but wider than the year-ago loss of 82 cents.
Revenues rose to $3.6 million from $1.6 million a year earlier, helped by higher license revenues and Hemgenix royalties under the CSL Behring collaboration. The top line missed the Zacks Consensus Estimate of $7 million.
Selling, general and administrative expenses rose 84% to $20.1 million on commercial hiring and higher professional, intellectual property and information technology costs tied to AMT-130 launch preparation. That spending reinforces the near-term loss profile.
PTC Therapeutics (PTCT - Free Report) and Wave Life Sciences (WVE - Free Report) give investors other Huntington's disease-related stocks to monitor. Their presence makes QURE's post-rally valuation discipline more important.
uniQure Has Some Estimate Support
The last earnings surprise was positive at 3.4%, and the current fiscal-year earnings estimate improved 2.3% over the past four weeks. QURE also had an Earnings Surprise Prediction of 12.0% ahead of the next expected report date.
Those data points help sentiment. They do not settle the larger questions around regulatory alignment, commercialization timing or the path to profitability.
QURE’s Balance Sheet Helps Offset the Risk
uniQure ended the first quarter with $586.6 million in cash, cash equivalents and investments. Management expects those resources to fund operations into the second half of 2029.
That runway gives the company time to pursue AMT-130 regulatory milestones and continue selected pipeline investment. It also reduces the immediate financing pressure common among clinical-stage biotechnology stocks.
The operating model has become cleaner as well. The remaining HEMGENIX supply obligations and minimum purchase commitments are expected to end after delivery of specified batches in mid-2026, without affecting future royalties or milestones.
Roche Holding AG (RHHBY - Free Report) , a broader healthcare peer, gives investors a more diversified comparison point. QURE remains the more concentrated AMT-130-driven story.
Why QURE’s Ratings Stay Mixed
The bottom line is that QURE's rally has improved the market's view of the story, but it has not removed the need for caution. The stock looks most relevant for investors comfortable with catalyst-driven biotechnology risk.
The stock currently carries a Zacks Rank #3 (Hold). That supports a wait-and-see stance after the rally, with AMT-130 still facing important regulatory and execution steps. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Style Scores show the split. QURE has a Momentum Score of B, suggesting constructive price action, but its Value Score of F, Growth Score of F and VGM Score of F show that it does not screen broadly well on traditional valuation, growth and blended factors. That mix fits a selective, catalyst-focused view rather than a broadly bullish call.